 Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Inflammatory arthropathy and flu outcome in patients treated with DMARD

Ann Rheum Dis: Inflammatory arthropathy and flu outcome in patients treated with DMARD

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

lue garrett disease

brittle bone disease treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article that aims to evaluate the outcome of seasonal flu in patients with inflammatory joint disease (IJD) and disease-modifying anti-rheumatic drugs (DMARD) The absolute and relative risks of COVID-19 , and summarize the results of recent research on the corresponding COVID-19 risks
.

COVID-19

In this cohort study, researchers used the Swedish National Registry to follow up 116989 IJD patients and matched population controls.
The subjects spanned four flu seasons (2015-2019)
.

The researchers quantified the absolute risk of hospitalization and death due to influenza, and compared IJD patients with controls through Cox regression
.

At the beginning of each flu season, researchers identified 71,556 patients with IJD who were actively treated with conventional synthetic DMARDs and biological disease mitigating antirheumatic drugs (bDMARDs)/targeted synthetic disease mitigating antirheumatic drugs (tsDMARDs), and estimated the same outcome The risks of different DMARD groups were compared through Cox regression

Each season, the average risk of hospitalization for IJD patients due to influenza is 0.
25%, and that of the general population is 0.
1%.
The corresponding rough HR is 2.
38 (95% CI 2.
21 to 2.
56), and after adjusting for comorbidities, it drops to 1.
44 (95% CI is 1.
33 to 1.
56)
.

For influenza that is on the death list, the corresponding figures are 0.

It can be seen that, in absolute terms, the number of COVID-19 cases in patients with IJD exceeds the average seasonal flu, but IJD causes the risk of hospitalization and death for the two infections to increase by 50%-100%, which depends to a large extent.
For related comorbidities
.

Overall, treatment with bDMARDs/tsDMARDs does not seem to increase the risk of hospitalization or death associated with seasonal influenza

In absolute terms, the number of COVID-19 cases in patients with IJD exceeds the average seasonal flu, but IJD causes the risk of hospitalization and death for the two infections to increase by 50%-100%, depending on the related mergers.

Original source:

Hannah Bower,et al.

Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.